Molecular targets for the therapeutic manipulation of apoptosis in bladder cancer

Journal of Urology

Volumn 165, Issue 3, 2001, Pages 946-954

  Duggan, Brian J ^a,b   Kelly, John D ^a   Keane, Patrick F ^a   Johnston, Samuel R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Biochemical; Bladder; Bladder neoplasms; Genetic markers; Genetics

Indexed keywords

ANTISENSE BCL 2 OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CISPLATIN; CYTOSINE DEAMINASE; FAS ANTIBODY; FAS LIGAND; FLUOROURACIL; PROTEIN ADP53; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; PROTEIN P63; PROTEIN P73; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT LYMPHOTOXIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; THYMIDINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER CANCER; CLINICAL TRIAL; CYTOKINE PRODUCTION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; META ANALYSIS; MOLECULAR EVOLUTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0035131763     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66582-2     Document Type: Review

References (140)

1. Antioncogenes and human cancer
2. The biology of colorectal cancer
3. Caspases: Killer proteases
4. A combinatorial approach defines specificities of members of the caspase family and granzyme B: Functional relationships established for key mediators of apoptosis
5. Potent and selective inhibition of gene expression by an antisense heptanucleotide
6. Two molecular pathways to transitional cell carcinoma of the bladder
7. Genetic alterations in bladder cancer
8. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma
9. A molecular genetic model of human bladder cancer
10. Carcinoma in situ of the bladder
11. Superficial bladder cancer: Progression and recurrence
12. Carcinoma in situ
13. Creation of human tumour cells with defined genetic elements
14. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins
15. p53 and the treatment of bladder cancer
16. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer
17. Telomerase activity in patients with transitional cell carcinoma
18. Subsequential telomerase activity in exfoliated urinary cells detects recurrent disease in bladder cancer after transurethral resection
19. Review of chromosome studies in urological tumours: Cytogenetics and molecular genetics of bladder cancer
20. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer
21. Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study
22. Multifocality of transitional cell carcinoma results from genetic instability of the entire transitional cell epithelium
23. Upper tract tumors in patients with primary bladder cancer followed for 15 years
24. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urological cancer
25. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients
26. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident
27. Epidemiology and environmental factors in urologic cancer
28. Epidemiology of bladder cancer
29. Mutations in the p53 gene in schistosomal bladder cancer: A study of 92 tumors from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumors
30. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
31. Human cancer syndromes: Clues to the origin and nature of cancer
32. Intake of vegetables, fruits, beta-caroteine, vitamin-C and vitamin supplements and cancer incidence among the elderly
33. Diet and bladder cancer in Spain: A multi-centre case-control study
34. Bladder-cancer incidence in relation to vegetable and fruit consumption: A prospective study of atomic-bomb survivors
35. Molecular genetics of bladder cancer
36. Molecular prognostic factors in bladder cancer
37. p53 mutations in bladder tumours inactivate the transactivation of the p21 and Baxgenes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy
38. Pussycats and baby tigers: Non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same!
39. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer
40. The influence of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer
41. The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years
42. p53 gene mutations in human urothelial carcinomas: Analysis by immunohistochemistry and single-strand conformation polymorphism
43. The molecular pathology of urological malignancies
44. Prevalence and clinical significance of her-2/neu, p53 and Rb expression in primary superficial bladder cancer
45. Apoptosis and its clinical significance for bladder cancer therapy
46. Selective bladder preservation by combination treatment of invasive bladder cancer
47. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
48. Urinary bladder lesions after the Chernobyl incident: Immunohistochemical analysis of p53, proliferating cell nuclear antigen, cyclin D1 and p21
49. Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: Correlation to clinical outcome
50. Long-term efficacy of intravesical bacillus Calmette-Geurin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation
51. p53 and p53-regulated genes in bladder cancer
52. Killer in search of a motive?
53. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
54. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death
55. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: Synergy with MYC and inhibition by BCL2 antisense
56. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
57. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
58. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer
59. Letter to the editor
60. Bcl-2/Bax expression and p53 gene status in human bladder cancer: Relationship to early recurrence with intravesical chemotherapy after resection
61. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer
62. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
63. Intravesical therapy for bladder cancer
64. Megadose vitamins in bladder cancer: A double-blind clinical trial
65. Expression of bcl-2 and bcl-X in bladder cancer
66. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression
67. Relationship of p53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder
68. Expression of apoptosis suppressing bcl-2 protein in transitional cell bladder tumours
69. Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: Overexpression and absence of variation in fibroadenomas
70. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors
71. Specificity of antisense oligonucleotides in vivo
72. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
73. Target dependence of antisense oligodeoxynucleotide inhibition of c-H-ras p21 expression and focus formation in T24-transformed NIH3T3 cells
74. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5 P cap region
75. Implication of RNA structure on antisense oligonucleotide hybridization kinetics
76. Effect of bcl-2 on Fas antigen-mediated cell death
77. Augmented intracellular glutathione inhibits Fas-triggered apoptosis of activated human neutrophils
78. Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells
79. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis
80. The E2F transcription factors: Key regulators of cell proliferation
81. Phosphorothioate oligodeoxynucleotide analogues
82. Mitomycin C in multiple superficial bladder tumors: Short-term therapy, long-term results
83. Accumulation of nuclear p53 and tumour progression in bladder cancer
84. WAF1, a potential mediator of p53 tumor suppression
85. The p21-Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cycline dependent kinases
86. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines
87. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/Waf-1/Cip-1 and/or p53 gene alterations
88. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells
89. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes
90. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
91. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa 2b: Results of a multicentric Italian study
92. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer
93. Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents
94. Direct in vivo gene transfer to urological organs
95. A novel gene delivery system using urothelial tissue engineered neo-organs
96. Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: Analysis of possible predictors of response free of tumor
97. Antisense oligodeoxyribonucleotide-directed cleavage of maternal mRNA in Xenopus oocytes and embryos
98. Talking point: A good antisense molecule is hard to find
99. p53 Tumor suppressor gene therapy for cancer
100. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
101. Preliminary report: The short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas
102. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
103. Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 596 human lung cancer cells
104. Introduction of wild-type p53 gene downregulates the expression of H-ras gene and suppresses the growth of bladder cancer cells
105. A novel tumor-specific gene therapy for bladder cancer
106. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy
107. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
108. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia
109. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
110. Chemosensitisation and delayed androgen independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
111. In vivo electrophoretic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats
112. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector
113. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer
114. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line
115. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo
116. Editorial: Gene therapy - A loss of innocence
117. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration
118. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect
119. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand
120. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II)
121. Improved production of adenovirus vectors expressing apoptotic transgene
122. Rationale and development of retinoblastoma (RB) tumor suppressor gene therapy for bladder cancer
123. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
124. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity
125. Demonstration of a rational strategy for human prostate cancer gene therapy
126. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells
127. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model
128. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder
129. Gene therapy of bladder cancer, cancer control
130. Adenovirus-mediated suicide gene therapy for experimental bladder cancer
131. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model
132. Immunotherapy for cancer by direct gene transfer into tumors
133. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biological activity, and lack of toxicity in humans
134. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
135. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia
136. In vivo gene transfer methods into bladder without viral vectors
137. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder
138. A combined analysis of European Organization for Research and treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer